

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				ATTY. DOCKET NO. 484112.417C1		APPLICATION NO. 09/684,883	
				APPLICANTS Bernard R. Brodeur			
				FILING DATE October 6, 2000		GROUP ART UNIT 1645	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
MN	AB	0301992 B1	5/24/95	EP			
MN	AC	0474313 B1	4/23/97	EP			
	AD						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
MN	AE	Aho et al., "A Comparative Analysis of Pilin Genes from Pathogenic and Nonpathogenic <i>Neisseria</i> Species," <i>Microbial Pathogenesis</i> 28:81-88, 2000.					
MN	AF	Bernardini et al., "Proteome Analysis of <i>Neisseria meningitidis</i> Serogroup A," <i>Proteomics</i> 4:2893-2926, 2004.					
MN	AG	Bhattacharjee et al., "Purification and Characterization of H.8 Antigen from Group B <i>Neisseria meningitidis</i> ," <i>Infection and Immunity</i> 56(4):773-778, 1988.					
MN	AH	Bjune et al., "Effect of Outer Membrane Vesicle Vaccine Against Group B Meningococcal Disease in Norway," <i>The Lancet</i> 338(8775):1093-1096, 1991.					
MN	AI	Drocourt et al., "Nucleotide Sequence of the Xylose Isomerase Gene from <i>Streptomyces violaceoniger</i> ," <i>Nucleic Acids Research</i> 16(19):9337, 1988.					
MN	AJ	Frasch et al., "Immune Responses of Adults and Children to Group B <i>Neisseria meningitidis</i> Outer Membrane Protein Vaccines," in <i>Bacterial Vaccines</i> 262-272, 1987.					
MN	AK	Frasch et al., "Outer Membrane Proteins of <i>Neisseria Meningitidis</i> : Structure and Importance in Meningococcal Disease," <i>Clinical and Investigative Medicine</i> 9(2):101-107, 1986.					
MN	AL	Gotschlich et al., "Human Immunity to the Meningococcus," <i>The Journal of Experimental Medicine</i> 129(6):1349-1365, 1969.					
MN	AM	Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations," <i>Journal of Molecular Biology</i> 183:1-12, 1985.					
MN	AN	Mandrell et al., "Human Immune Response to Meningococcal Outer Membrane Protein Epitopes after Natural Infection or Vaccination," <i>Infection and Immunity</i> 57(5):1590-1598, 1989.					
EXAMINER /Albert M Navarro/				DATE CONSIDERED 02/26/2007			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

Date: February 15, 2007

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 484112.417C1	APPLICATION NO. 09/684,883
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Bernard R. Brodeur	
		FILING DATE October 6, 2000	GROUP ART UNIT 1645
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
MN	BB	Martin et al., "Highly Conserved <i>Neisseria meningitidis</i> Surface Protein Confers Protection against Experimental Infection," <i>Journal of Experimental Medicine</i> 185(7):1173-1183, 1997.	
MN	BC	Saukkonen et al., "Comparative Evaluation of Potential Components for Group B Meningococcal Vaccine by Passive Protection in the Infant Rat and <i>in vitro</i> Bactericidal Assay," <i>Vaccine</i> 7:325-328, 1989.	
MN	BD	Saukkonen et al., "Protective Efficacy of Monoclonal Antibodies to Class 1 and Class 3 Outer Membrane Proteins of <i>Neisseria meningitidis</i> B:15:P1.16 in Infant Rat Infection Model: New Prospects for Vaccine Development," <i>Microbial Pathogenesis</i> 3:261-267, 1987.	
	BE		
	BF		
	BG		
	BH		
	BI		
	BJ		
	BK		
	BL		
	BM		
	BN		
	BO		
	BP		
	BQ		
	BR		
EXAMINER /Albert M Navarro/		DATE CONSIDERED 02/26/2007	
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).			